LBRX Key Statistics, Chart & Performance
The current stock price of LBRX is 23.91 USD. In the past month the price increased by 7.95%.
LBRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LBRX.
LBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBRX. No worries on liquidiy or solvency for LBRX as it has an excellent financial health rating, but there are worries on the profitability.
LBRX Financial Highlights
Over the last trailing twelve months LBRX reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS decreased by -905.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.67% | ||
| ROE | -20.34% | ||
| Debt/Equity | 0 |
LBRX Forecast & Estimates
9 analysts have analysed LBRX and the average price target is 43.35 USD. This implies a price increase of 81.3% is expected in the next year compared to the current price of 23.91.
LBRX Ownership
About LBRX
Company Profile
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Company Info
LB PHARMACEUTICALS INC
One Pennsylvania Plaza, Suite 1025
New York City NEW YORK US
Employees: 16
Phone: 19174506581
LB PHARMACEUTICALS INC / LBRX FAQ
What does LBRX do?
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Can you provide the latest stock price for LB PHARMACEUTICALS INC?
The current stock price of LBRX is 23.91 USD. The price increased by 1.4% in the last trading session.
Does LBRX stock pay dividends?
LBRX does not pay a dividend.
What is the ChartMill rating of LB PHARMACEUTICALS INC stock?
LBRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for LBRX stock?
LB PHARMACEUTICALS INC (LBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).
Can you provide the number of employees for LB PHARMACEUTICALS INC?
LB PHARMACEUTICALS INC (LBRX) currently has 16 employees.